Celldex Logo.jpg
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
February 24, 2024 14:05 ET | Celldex Therapeutics, Inc.
- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups -- Sustained activity with rapid...
TilrayBrands_Logo_FullColor_RBG_Horiz-01.png
Tilray Medical salue le Bundestag allemand et l’adoption historique de la loi sur le cannabis à usage médicinal en Allemagne
February 24, 2024 09:13 ET | Tilray Brands, Inc.
COLOGNE, Allemagne et NEUMÜNSTER, Allemagne, 24 févr. 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (« Tilray ») (Nasdaq : TLRY ; TSX : TLRY), une société mondiale de premier plan opérant...
Alvotech_logo.jpg
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
February 23, 2024 20:15 ET | Alvotech
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership...
Alvotech and Teva An
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
February 23, 2024 20:15 ET | Alvotech
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S.  SIMLANDI is the first biosimilar approval under the strategic partnership...
Alvotech hlýtur mark
Alvotech hlýtur markaðsleyfi í Bandaríkjunum fyrir Simlandi, líftæknilyfjahliðstæðu við Humira í háum styrk
February 23, 2024 20:15 ET | Alvotech
Simlandi (AVT02) verður fyrsta líftæknilyfjahliðstæðan á markaði í Bandaríkjunum sem er útskiptanleg við Humira í háum styrkMarkaðsleyfi með útskiptanleika getur veitt einkarétt til markaðssetningar á...
Regency-Logo2012-RGB.jpg
Regency Centers Announces Whole Foods Market Anchored Development in Central Connecticut
February 23, 2024 18:44 ET | Regency Centers Corporation
CHESHIRE, Conn., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Regency Centers has acquired the land on which it plans to develop Cheshire Crossing, a 152,000-square foot shopping center anchored by Whole Foods...
logo_egain.png
eGain presenteert de nieuwe op AI gebaseerde kennistechnologie tijdens Call Centre World 2024 te Berlijn
February 23, 2024 18:37 ET | eGain Corporation
SUNNYVALE, Calif. en NEWBURY, Verenigd Koninkrijk, Feb. 24, 2024 (GLOBE NEWSWIRE) -- eGain (NASDAQ: EGAN), het belangrijkste op AI gebaseerde kennisplatform voor klantbetrokkenheid, kondigde vandaag...
logo_egain.png
eGain exposera ses nouveautés dans le domaine des connaissances IA au salon Call Centre World 2024 à Berlin
February 23, 2024 18:37 ET | eGain Corporation
SUNNYVALE, Calif. et NEWBURY, Royaume-Uni, 24 févr. 2024 (GLOBE NEWSWIRE) -- eGain (NASDAQ : EGAN), la plus grande plateforme de connaissances IA pour l’engagement client, a annoncé aujourd’hui...
logo_egain.png
eGain stellt neue KI-Wissensfunktionen auf der Call Centre World 2024 in Berlin vor
February 23, 2024 18:37 ET | eGain Corporation
SUNNYVALE, Kalifornien und NEWBURY, Vereinigtes Königreich, Feb. 24, 2024 (GLOBE NEWSWIRE) -- eGain (NASDAQ: EGAN), die führende KI-Wissensplattform für Kundenbindung, hat heute bekanntgegeben,...
logo_egain.png
In occasione del Call Centre World 2024 di Berlino, eGain presenterà le nuove funzionalità di conoscenza basata sull'intelligenza artificiale
February 23, 2024 18:37 ET | eGain Corporation
SUNNYVALE, California e NEWBURY, Regno Unito, Feb. 24, 2024 (GLOBE NEWSWIRE) -- eGain (NASDAQ: EGAN), la piattaforma di conoscenza basata sull’intelligenza artificiale leader per il coinvolgimento...